Pharma partnership terms that protect your pipeline when the science goes sideways

The fundamental tension in any pharma partnership is time. A small biotech running a Phase II trial might have 18 months of runway. Its large-cap partner operates on a five-year portfolio planning cycle. Both parties sign a term sheet as if they share the same urgency, and then spend the next decade discovering they do not. The mismatch is not a negotiating failure; it is structural, and it has to be priced into the deal architecture before anyone signs.

Rising Treasury yields in 2026 have tightened the screws further. With the 10-year yield staying elevated, the risk-adjusted net present valuenet present valueNet Present Value is the sum of an investment's future cash flows discounted to today, minus the initial outlay. A positive NPV signals value creation.View full definition → of a late-stage asset compresses. Partners know this. They are using the macro environment to push upfronts down and weight more value into back-end milestones that may never be reached. A biotech CFO who accepts that logic without a fight is ceding negotiating ground that will not come back.

Building a milestone schedule that actually pays out

The first move is to mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition → every regulatory gate to a specific payment trigger, and then add a secondary trigger for timeline slippage caused by the partner. Most term sheets list milestones like "IND filing," "end of Phase II meeting," "NDA submission," and "first commercial sale." What they omit is who controls each gate. If the partner is responsible for regulatory strategy post-licensing and they delay an NDA submission by 18 months to manage their internal portfolio, your milestone does not trigger. You have no leverage unless the contract assigns financial consequences to that delay.

Build in a "diligence clock": a rolling 12-month review that requires the partner to demonstrate that the asset is on the development plan they committed to at signing. Roche's collaborations with smaller biotechs have used this mechanism in various forms. If the asset slips from the partner's active pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → without formal notice and consent, the rights should revert or a predefined compensatory payment should vest.

Second, negotiate milestone definitions at the molecular level. "Positive Phase III results" is not a definition. Define it: the primary endpoint achieved at the pre-specified alpha level, in the ITT population, with a hazard ratio or effect size agreed in advance. AstraZeneca's 2023 collaboration structure with Daiichi Sankyo on antibody-drug conjugates set a useful precedent here: milestone payments were tied to specific regulatory designations (Breakthrough Therapy, Priority Review) in addition to trial outcomes, because those designations have economic value to the partnering company and are partially within its control.

Third, split your milestones into clinical, regulatory, and commercial tranches. Do not let a partner collapse them. Each tranche carries a different risk profile. Clinical milestones reflect your science. Regulatory milestones partly reflect the partner's relationship with the FDA or EMA and their submission quality. Commercial milestones depend on the partner's sales force, pricing strategy, and market access capability. A CFO who values the pre-revenue pipeline using risk-adjusted NPVNPVNet Present Value is the sum of an investment's future cash flows discounted to today, minus the initial outlay. A positive NPV signals value creation.View full definition → will already have these tranches separated in the model; the contract should mirror that structure.

How do you protect royalty rates when a partner has control over pricing?

The short answer: tiered royalties keyed to net sales thresholds, with a floor that survives any discounting the partner applies to win formulary access. The standard pitfall is accepting a royalty on "net sales" without defining the deductions. Partners routinely subtract co-pay assistance, managed care rebates, distribution fees, and chargebacks before calculating the royalty base. In US markets with aggressive PBM negotiations, those deductions can reduce net sales to 60-70% of gross. Negotiate a cap on allowable deductions, typically 20-25% of gross, and define it by category.

Also negotiate a minimum annual royalty during the commercial phase. If the partner under-promotes the asset, a floor payment forces a choice: either invest in the brand or return the rights.

The structural mistakes that sink milestone deals in practice

The most common failure is accepting a lump-sum upfront in exchange for reduced milestones. The logic looks sound when you need capital to fund the next trial. The problem is that upfronts are taxed as ordinary income and carry no contingency. Milestones, structured correctly, can be tied to events you influence. Swapping future optionality for present cash is rational only if your burn rateburn rateBurn rate is the speed at which a company spends its cash reserves, usually measured per month, before reaching profitability or raising more funding.View full definition → and runway analysis shows you will not survive to collect those milestones otherwise. Run that calculation explicitly, not as a gut check.

A second failure is ignoring the change-of-control clause. If your large-cap partner is acquired, the new parent may deprioritise your asset entirely. Ensure the agreement includes a change-of-control provision that either vests a portion of remaining milestones immediately or grants you a buy-back right at a pre-agreed formula. Bristol Myers Squibb's acquisition of Celgene in 2019 left several smaller partners renegotiating development commitments that the new parent had no interest in honouring. That was not a legal failure; it was a drafting failure.

The third mistake is allowing the partner to hold IP rights to combination therapies or reformulations. If your molecule is later developed as a fixed-dose combination with another partner asset, the economics of that combination may sit entirely outside your original agreement. Define the scope of licensed IP tightly and require a separate negotiation for any new indication or formulation.

Finally, watch the sublicensing terms. If the partner can sublicense to a third party in ex-US markets, your royalty on those sublicensed sales is typically a fraction of what you would earn from a direct license. Either negotiate the sublicense royalty at the time of deal signing, or retain approval rights over sublicense terms.

Start this week

• Pull your current or draft term sheet and map each milestone to its controlling party. Flag any milestone the partner controls without a diligence clock.
• Model three royalty scenarios using the gross-to-net deduction caps you have accepted (current language, 20% cap, 25% cap). Quantify the difference in NPV across a 10-year commercial period.
• Draft a change-of-control provision with your legal counsel and benchmark it against public deal disclosures from the last three years. BMS-Celgene and Pfizer-Arena Pharmaceuticals both offer instructive public filings.
• Identify which milestones in your model carry regulatory designation triggers (Breakthrough Therapy, Fast Track, PRIME in Europe) and verify that they appear in the commercial milestone schedule, not just as narrative footnotes.

Milestone-based deal structures are not inherently protective; they are only as strong as the definitions and enforcement mechanisms built into them. A CFO who treats the milestone schedule as a financial model input rather than a negotiating output will spend years watching value leak through imprecise language.

The full course on this sector:Finance in Biotech & MedTech.